BLOOD PLASMA BIOMARKERS APPLICABLE FOR COMBINATION THERAPIES WITH USING BEVACIZUMAB IN TREATING PANCREATIC CANCER Russian patent published in 2016 - IPC G01N33/574 A61K39/395 A61P35/00 

FIELD: medicine.

SUBSTANCE: there is involved (a) determining the expression level of one or more of VEGFA, VEGFR2 and PLGF proteins in a blood plasma sample taken from the patient's body; and (b) administering bevacizumab in a combination with a chemotherapy regimen in the patient having the increased expression level of one or more of VEGFA, VEGFR2 and PLGF in relation to reference expression levels detected in the patients diagnosed with pancreatic cancer. Pancreatic cancer represents metastatic pancreatic cancer, and the chemotherapy regimen includes gemcitabine and erlotinib. There is also presented a method for identifying in vitro the patient susceptible or sensitive to adding bevacizumab to the chemotherapy regimen, using bevacizumab to improve the therapeutic effect of the chemotherapy regimen on the patient suffering from pancreatic cancer, using specific probes to produce a diagnostic composition applicable to predict a response or sensitivity to adding bevacizumab to the chemotherapy regimen in the above patient, using a polypeptide to determine the expression level of one or more of VEGFA, VEGFR2 and/or PLGF, as well as the kit that includes the above polypeptide.

EFFECT: group of inventions provides identifying the patient suffering from metastatic pancreatic cancer, and increasing the therapeutic effect of the chemotherapy regimen on the above patient by adding bevacizumab to the chemotherapy regimen including gemcitabine and erlotinib.

29 cl, 14 dwg, 8 tbl, 5 ex